HIV
Conference Coverage
Maraviroc shows potential for HIV PrEP in women
DURBAN, SOUTH AFRICA – Maraviroc shows promise as an alternative to Truvada for HIV pre-exposure prophylaxis.
Conference Coverage
Long-acting all-injectable HIV therapy successful in phase 2b
DURBAN, SOUTH AFRICA – The era of all-injectable, long-acting antiretroviral therapy for HIV may be drawing closer.
News
Major depressive disorder increases acute MI risk in HIV
Key clinical point: Major depressive disorder is associated with a significant increase in the risk of acute myocardial infarction in adults...
Conference Coverage
With HIV PrEP, benefits outweigh resistance risk
DURBAN, SOUTH AFRICA – The benefit of oral daily chemoprophylaxis against HIV infection in at-risk individuals far outweighs the risk.
News
Ombitasvir/paritaprevir-based HCV regimens perform well in HIV coinfection
DURBAN, SOUTH AFRICA – All-oral regimens featuring two or three direct-acting antiviral agents proved safe, effective, and well tolerated for...
News
Better use of lab testing tools needed to beat HIV/AIDS
Major improvements in HIV laboratory capacity utilization are needed in low- and middle-income countries if the 90-90-90 HIV/AIDS targets are to...
News
Integrated PrEP and ART prevents HIV transmission in couples
In committed couples, HIV transmission from positive partners dropped from an expected incidence of more than 5% to less than 0.5% per year when...
News
HIV research update: Early August 2016
The HIV epidemic serves as an amplifier of TB outbreaks by providing a reservoir of susceptible hosts, a recent study found. Read about this and...
Conference Coverage
Anal cancer in HIV-infected patients: to screen or not?
Conference Coverage
Cancer trends shifting in HIV-positive patients
Key clinical point: HIV-infected persons in North America have roughly a 1 in 25 cumulative lifetime risk of developing lung cancer, Kaposi’s...